32
Participants
Start Date
June 30, 2009
Primary Completion Date
June 30, 2012
Study Completion Date
December 31, 2013
Bevacizumab/Irinotecan
Bevacizumab 10mg/kg D1 Irinotecan 125mg/m2 D1 (without enzyme-inducing antiepileptic drugs \[EIAEDs\] or 340mg/m2 for patients on EIAEDs) every 2 weeks
Seoul National University Hospital, Seoul
Lead Sponsor
Seoul National University Hospital
OTHER
Clinical Research Center for Solid Tumor, Korea
OTHER